|
KMID : 0363220210590080644
|
|
Korean Journal of Dermatology
2021 Volume.59 No. 8 p.644 ~ p.648
|
|
|
Cutaneous Adverse Events of Anti-Programmed Cell Death Receptor-1 Antibody: Two Case Reports and a Literature Review
|
|
Lim Joon-Soo
Kim Hyun-Hee
Kwon Eun-Sun
Myung Ki-Bum
Cheong Seung-Hyun
|
|
|
Abstract
|
|
|
|
The introduction of immune checkpoint inhibitors, including anti-programmed cell death receptor-1 antibodies (anti-PD-1 Ab), such as nivolumab and pembrolizumab, represents a major breakthrough in cancer therapy. The PD-1 pathway inhibits T cell activation, maintaining a normal and balanced immune response. Anti-PD-1 Ab induces T cell activity by inhibiting the suppressive effect of PD-1 signaling on T cells. Excessive stimulation of T cells represents a potential mechanism for multiple skin lesions. To the best of our knowledge, reports on cutaneous adverse effects during treatment with anti-PD-1 Ab are limited in the dermatological literature of Korea. Herein, we report two rare cases of nivolumab-induced lichenoid drug eruption and pembrolizumab-induced psoriasis.
|
|
|
KEYWORD
|
|
|
Adverse events, Immune checkpoint, Nivolumab, Pembrolizumab, Programmed death receptor-1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|